Minnesota-based leading medical device manufacturer Medtronic, Inc.'
s (MDT - Analyst Report
) Attain Performa Model 4298 quadripolar lead, and the Viva Quad XT and Viva Quad S cardiac resynchronization therapy defibrillators (CRT-D) have recently received the U.S. Food and Drug Administration (FDA) approval.
With these sanctions, the new system will now enable surgeons to provide optimal and more efficient Cardiac Resynchronization Therapy (CRT) to heart-failure patients.
Following the news release, Medtronic's share prices rose 1.4% to eventually close at $62.15 on Friday.
An individual whose heart does not beat sufficiently on its own needs a CRT heart device that sends small, undetectable electrical impulses to the lower chambers of the heart to help them beat together in a more synchronized manner.
Attain Quadripolar Lead
Quadripolar leads are insulated wires with four electrodes that connect a heart device and a patient's heart. These wires are used to transmit information signals from one's heart to the device and deliver electrical impulses back to the heart, making it beat efficiently.
Medtronic's Attain Performa Model 4298 left-heart quadripolar lead offers supplementary options to physicians to treat different patient anatomies. Its unique feature includes 16-pacing configurations and shorter spacing between the two center electrodes. The Model 4298 lead has a canted shape and steroid on all four electrodes for lower pacing thresholds. This Attain Performa portfolio has already received the CE Mark in Europe in Mar 2013.
Compared to traditional leads, the additional pacing configurations offered by this system helps surgeons optimize CRT delivery while the narrow-spaced bipole helps avoid phrenic nerve capture. This system can thus offer better patient care by reducing the incidence of phrenic nerve stimulation that can result in partial or complete respiratory insufficiency as a side effect in heart patients.
What is Viva CRT-D?
Medtronic's Viva Quad XT and Viva Quad S are two CRT-D devices that utilize two different algorithms. While the Viva XT CRT-D device incorporates the company's AdaptiveCRT algorithm, the Viva S device features the Ensure CRT Suite.
The company's proprietary Adaptive CRT algorithm delivers physiologic pacing by preserving a patient's normal heart rhythms and automatically adjusts to patients' needs to customize therapy. This system also includes the VectorExpress technology, which reduces lead programming time to two minutes. This technology provides helpful clinical information to physicians to choose optimal pacing configurations for each patient.
On the other hand, the Ensure CRT Suite consists of five integrated algorithms that automatically work in tandem to ensure efficient CRT delivery during challenging conditions. This system features three algorithms that can maximize CRT response even in the presence of atrial fibrillation.
Both these CRT-D devices boast increased device longevity and promise to escalate patient comfort. Medtronic expects to make the quadripolar leads and the two CRT-D devices available to physicians by mid-September.
Medtronic is dedicated to advancing patient care for heart failure individuals ever since its first commercialized cardiac resynchronization therapy came into being in the U.S. Management expects the FDA nod for the new Attain Performa lead and the two Viva Quad devices will add yet another feather to its cap.
Currently, Medtronic carries a Zacks Rank #2 (Buy). Other well-ranked stocks in the Medical Products industry include OraSure Technologies, Inc. (OSUR - Snapshot Report
) , Abaxis, Inc. (ABAX - Analyst Report
) and AtriCure, Inc. (ATRC - Snapshot Report
) . While OraSure sports a Zacks Rank #1 (Strong Buy), Abaxis and AtriCure hold a Zacks Rank #2 (Buy) each.